NASDAQ:XENE

Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

Xenon Pharmaceuticals logo
$37.04 -0.52 (-1.38%)
Closing price 04:00 PM Eastern
Extended Trading
$37.03 -0.01 (-0.01%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Xenon Pharmaceuticals Stock (NASDAQ:XENE)

Advanced

Key Stats

Today's Range
$36.81
▼
$37.97
50-Day Range
$33.49
▼
$58.65
52-Week Range
$33.38
▼
$72.66
Volume
1.08 million shs
Average Volume
1.39 million shs
Market Capitalization
$3.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.15
Consensus Rating
Moderate Buy

Company Overview

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells.

Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions.

Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America. Its work includes discovering and developing therapies intended to address conditions with significant unmet medical needs.

AI Generated. May Contain Errors.

Xenon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

XENE MarketRank™: 
3.0187645528 of 5 stars

Xenon Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 346th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xenon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Xenon Pharmaceuticals has a consensus price target of $71.15, representing about 91.9% upside from its current price of $37.09.

  • Amount of Analyst Coverage

    Xenon Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Xenon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($4.63) to ($4.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xenon Pharmaceuticals is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xenon Pharmaceuticals is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xenon Pharmaceuticals has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.85% of the float of Xenon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 6.36.
  • Change versus previous month

    Short interest in Xenon Pharmaceuticals has recently increased by 0.20%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Xenon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Xenon Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Xenon Pharmaceuticals has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Xenon Pharmaceuticals this week, compared to 5 articles on an average week.
  • Cluster Insider Buying

    2 insiders have purchased shares of Xenon Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $1,255,353.00 in company stock, which represents 0.0350% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Xenon Pharmaceuticals insiders have bought 294.79% more of their company's stock than they have sold. Specifically, they have bought $1,681,200.00 in company stock and sold $425,847.00 in company stock.

  • Percentage Held by Insiders

    2.91% of the stock of Xenon Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xenon Pharmaceuticals' insider trading history.
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XENE Stock News Headlines

HC Wainwright Has Negative Outlook for XENE FY2026 Earnings
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Xenon (XENE) Q3 2026 Earnings Call Transcript
See More Headlines

XENE Stock Analysis - Frequently Asked Questions

Xenon Pharmaceuticals' stock was trading at $44.82 at the beginning of the year. Since then, XENE shares have decreased by 17.3% and is now trading at $37.0850.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Monday, November, 9th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.02.
Read the conference call transcript
.

Xenon Pharmaceuticals (XENE) raised $44 million in an IPO on Friday, October 17th 2014. The company issued 4,000,000 shares at $10.00-$12.00 per share.

Top institutional investors of Xenon Pharmaceuticals include State Street Corp (2.13%), Pictet Asset Management Holding SA (1.52%), American Century Companies Inc. (0.99%) and Marshall Wace LLP (0.93%). Insiders that own company stock include Ian Mortimer, Gary Patou, Sherrington Robin, Andrea Difabio, Steven Gannon, Gillian Cannon, Christopher John Kenney and Sherry Aulin.
View institutional ownership trends
.

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Ford Motor (F), Micron Technology (MU) and AbbVie (ABBV).

Company Calendar

Last Earnings
11/09/2026
Today
11/20/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:XENE
CIK
1582313
Employees
364
Year Founded
1996

Price Target and Rating

High Price Target
$97.00
Low Price Target
$46.00
Potential Upside/Downside
+92.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$345.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.81%
Return on Assets
-37.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.19
Quick Ratio
21.19

Sales & Book Value

Annual Sales
$7.50 million
Price / Sales
476.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.86 per share
Price / Book
3.12

Miscellaneous

Outstanding Shares
96,670,000
Free Float
93,853,000
Market Cap
$3.58 billion
Optionable
Optionable
Beta
0.11

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:XENE) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners